What Is Biased Agonism? Why New GLP-1 and Multi-Agonist Peptides Are Being Engineered to Signal Differently

The next generation of metabolic peptides is not only about targeting more receptors.

Researchers are also trying to make drugs interact with the same receptor in smarter ways.

This concept is called:

biased agonism.

Instead of switching a receptor fully “on”, a biased agonist can favour one signalling pathway inside the cell over another.

That may sound like a small molecular detail.

It is not.

Biased agonism could potentially affect:

• how long a receptor keeps signalling
• how quickly it becomes desensitised
• whether it is pulled inside the cell
• glucose regulation
• appetite effects
• gastrointestinal tolerability
• overall effectiveness

A 2026 Trends in Pharmacological Sciences article described signalling bias as a promising strategy for improving incretin therapeutics and highlighted new structural discoveries that could allow scientists to deliberately design biased GLP-1 receptor agonists. (PubMed⁠)

First: What Happens When a Peptide Activates a Receptor?

Many metabolic peptide receptors belong to a large family called:

G protein-coupled receptors, or GPCRs.

These include receptors for:

• GLP-1
• GIP
• glucagon
• amylin-related signalling

When a peptide binds to one of these receptors, the receptor changes shape.

That triggers signalling inside the cell.

But there is not just one possible signal.

The same receptor can activate several intracellular pathways.

What Does GLP-1 Receptor Signalling Normally Do?

When GLP-1 activates its receptor, one important pathway involves a G protein known as:

Gs

This increases production of:

cyclic AMP, or cAMP.

cAMP helps drive many of GLP-1’s recognised effects, including insulin-related signalling.

But GLP-1 receptor activation can also recruit proteins called:

β-arrestins.

These proteins influence:

• receptor signalling
• receptor trafficking
• receptor internalisation
• desensitisation

So one receptor can essentially send several different messages.

What Does “Biased” Mean?

A biased agonist does not activate every signalling pathway equally.

For example, one GLP-1 receptor agonist might strongly favour:

G protein / cAMP signalling

while producing relatively little:

β-arrestin recruitment.

Another agonist could produce a more balanced response.

That difference is known as signalling bias.

Why Might Scientists Want More cAMP and Less β-Arrestin?

One reason is receptor internalisation.

When β-arrestin is recruited, the receptor can be pulled away from the cell surface into the cell.

This process is called:

receptor internalisation.

Reducing that process may leave more receptors available at the surface to continue signalling.

A 2026 study found that experimentally reducing β-arrestin recruitment and GLP-1 receptor internalisation prolonged G-protein signalling and increased cAMP generation. (PubMed⁠)

Does That Mean β-Arrestin Is Bad?

No.

β-arrestins have important biological functions.

They are not simply unwanted signalling molecules.

The real question is whether the balance between signalling pathways can be optimised for a particular therapeutic goal.

A drug designed for obesity may require a different signalling profile from one designed primarily for diabetes.

Could Biased Agonism Make a Drug Stronger?

Potentially.

If a receptor remains active at the cell surface for longer, the same molecule may produce more sustained signalling.

That could theoretically improve:

• glucose regulation
• appetite suppression
• duration of action

without simply increasing the dose.

Preclinical experiments support this idea.

A 2026 study of modified GLP-1 receptor agonists found that G-protein-biased compounds showed reduced β-arrestin recruitment, altered receptor trafficking and prolonged cAMP signalling. (PubMed⁠)

Could It Also Reduce Side Effects?

This is one of the most interesting possibilities.

GLP-1-related gastrointestinal effects such as:

• nausea
• vomiting
• malaise

can limit treatment.

Researchers are investigating whether different signalling pathways contribute differently to therapeutic effects and adverse effects.

A 2026 preclinical study found that cAMP-biased GLP-1 receptor agonism maintained glucose-lowering effects while producing less malaise and vomiting in mammalian models. (PubMed⁠)

That does not yet prove that signalling bias will eliminate nausea in humans.

But it provides a strong reason to keep studying the approach.

Why Is Receptor Internalisation Important?

Imagine receptors on the surface of a cell as communication antennas.

A drug activates them.

If those receptors are rapidly pulled inside the cell, fewer remain available on the surface.

The cell may become temporarily less responsive.

This contributes to a phenomenon called:

desensitisation.

A biased agonist that causes less internalisation may potentially maintain signalling for longer.

Is This Already Being Used in Real Drug Development?

Yes.

Biased signalling is no longer purely theoretical.

Several modern metabolic compounds have signalling profiles that favour particular intracellular pathways.

Research increasingly considers signalling bias alongside traditional questions such as:

• receptor potency
• half-life
• dosing frequency
• receptor selectivity

A 2026 review of GLP-1 receptor biology identified biased agonist design as one of the major approaches being explored to improve next-generation metabolic therapies. (PubMed⁠)

What Is CT-388?

CT-388 is a useful example.

It is a peptide-based dual agonist targeting:

GLP-1 + GIP

and was deliberately designed to show cAMP-biased signalling at both receptors.

In laboratory experiments, CT-388 produced minimal receptor internalisation compared with the natural hormones.

It subsequently progressed into human clinical testing. (PubMed⁠)

What Did CT-388 Show in Humans?

In an early Phase 1 trial involving people with overweight or obesity, CT-388 produced:

• body-weight reduction
• appetite suppression
• improved glycaemic control

and was generally tolerated in a manner consistent with other incretin therapies. (PubMed⁠)

The study does not prove that signalling bias alone caused those effects.

But it provides an important real-world example of biased receptor engineering moving from cell biology into clinical development.

What About Ecnoglutide?

Ecnoglutide is another important example within the broader biased-agonist field.

It was designed as a cAMP-biased GLP-1 receptor agonist.

The idea is to favour G-protein signalling while reducing pathways associated with rapid receptor internalisation.

Ecnoglutide has since progressed through substantial clinical development, illustrating that biased agonism is becoming a practical drug-design strategy rather than an experimental curiosity.

What About Tirzepatide?

Tirzepatide is also interesting from a signalling perspective.

Studies have shown that its GLP-1 receptor signalling profile differs from that of native GLP-1.

Researchers have therefore discussed signalling bias as one possible contributor to its pharmacological profile.

But tirzepatide’s effects cannot be explained by biased signalling alone.

It also activates the GIP receptor, so multiple mechanisms are involved.

Could Retatrutide Be Engineered This Way Too?

Potentially.

Retatrutide already has the difficult task of balancing activity across:

• GIP
• GLP-1
• glucagon

Future triple agonists may therefore be designed not only around:

how strongly each receptor is activated

but also:

which signalling pathway each receptor activates once engaged.

That adds another level of engineering.

What Would a “Biased Triple Agonist” Mean?

It could theoretically mean that one molecule:

• favours cAMP signalling at GLP-1R
• uses a different signalling balance at GIPR
• has another carefully tuned profile at the glucagon receptor

This would allow scientists to control not merely receptor selection, but intracellular signalling quality.

That is far more sophisticated than simply creating a molecule that activates three receptors.

Has This Been Tested?

Yes, at least preclinically.

A 2026 study investigated biased dual GLP-1/glucagon agonists.

Researchers found that a small amino-acid modification could shift signalling toward cAMP and away from β-arrestin recruitment.

A biased co-agonist produced robust weight reduction in animal models, supporting the idea that signalling bias could be deliberately incorporated into future multi-agonist peptides. (PubMed⁠)

Why Can One Amino Acid Matter So Much?

Peptides interact with receptors with extraordinary precision.

Changing even one amino acid can alter:

• receptor affinity
• receptor conformation
• signalling pathway preference
• stability
• duration of action

The 2026 biased dual-agonist study found that modifying a conserved aspartate residue was sufficient to create a strong preference for cAMP signalling. (PubMed⁠)

This demonstrates how modern peptide engineering is becoming increasingly precise.

How Do Scientists Know Which Receptor Shape Produces Bias?

Structural biology is helping.

Techniques such as:

cryo-electron microscopy

allow scientists to visualise receptor-drug complexes at extremely high resolution.

In 2026, researchers identified movement of a region called extracellular loop 3 as an important structural feature influencing GLP-1 receptor signalling bias. (PubMed⁠)

That potentially allows researchers to design drugs deliberately around receptor shape.

Why Is That a Big Deal?

Historically, drug discovery often involved:

1. making many molecules
2. testing them
3. seeing which worked

Increasingly, researchers can examine receptor structure and ask:

What molecular change would make this receptor favour the pathway we want?

That moves drug development toward rational signalling design.

Could Biased Agonism Reduce Tolerance?

Possibly.

If reduced receptor internalisation prevents repeated signalling from causing rapid desensitisation, biased agonists might maintain their effects differently over time.

But long-term human evidence is still limited.

Weight-loss plateaus involve many biological adaptations beyond receptor desensitisation, so biased signalling should not be treated as a simple solution to tolerance.

Could It Help With Gastrointestinal Side Effects?

Potentially, but this remains an active research question.

If the pathways responsible for:

glucose control and appetite reduction

can be separated partly from those contributing to:

nausea and vomiting,

then biased agonism could theoretically improve the therapeutic window.

Preclinical evidence provides support for this possibility, but large human trials are needed. (PubMed⁠)

Could Two Drugs Target the Same Receptor but Feel Completely Different?

Yes.

This is one of the major implications of biased agonism.

Two compounds could both be described as:

GLP-1 receptor agonists

but differ in:

• binding strength
• receptor residence time
• cAMP signalling
• β-arrestin recruitment
• receptor internalisation
• brain penetration
• half-life

That means the receptor name alone does not completely describe the drug.

Why Does This Matter for Comparing New Peptides?

People often compare emerging peptides purely by counting receptors:

one receptor,

two receptors,

three receptors.

But this misses an important dimension.

A future drug could potentially outperform another compound targeting the exact same receptors because it produces a better intracellular signalling pattern.

So the next generation of peptide competition may involve:

signal quality as well as receptor quantity.

Is Biased Agonism Only Relevant to GLP-1?

No.

Many GPCRs are capable of biased signalling.

That includes receptors involved in:

• GIP
• glucagon
• appetite regulation
• cardiovascular biology

A 2026 review of GPCR signalling in appetite regulation described biased signalling and receptor trafficking as important emerging themes in the development of metabolic therapies. (PubMed⁠)

Could Amylin Receptors Also Be Engineered More Selectively?

The amylin field is approaching a related problem from another direction.

Compounds such as eloralintide attempt to selectively target particular amylin receptor configurations.

That is not identical to biased agonism.

But the philosophy is similar:

do not simply activate everything equally.

Instead, identify the receptor or signal most associated with the desired effect.

What Is the Difference Between Receptor Selectivity and Signalling Bias?

This distinction is useful.

Receptor selectivity asks:

Which receptor does the drug activate?

For example:

GLP-1R versus GIPR.

Signalling bias asks:

Once that receptor is activated, which intracellular pathway does it favour?

A sophisticated future peptide could therefore be engineered for both:

receptor selectivity

and

signalling bias.

Could This Produce More Powerful Drugs Without Adding More Receptors?

Potentially.

This is one of the biggest reasons biased agonism matters.

The industry does not necessarily need to keep adding:

fourth,

fifth,

sixth receptors.

Another strategy is to make existing receptor activation more efficient.

A carefully engineered single or dual agonist could potentially compete with a broader multiagonist if its signalling profile is better optimised.

Does This Challenge the Idea That “More Receptors = Better”?

Yes.

The newest research suggests that future drug design may involve several variables:

• number of receptors
• balance between receptors
• signalling bias at each receptor
• half-life
• tissue targeting
• receptor internalisation

That creates a much richer picture than simply counting receptor targets.

Could Biased Agonism Become Part of Reta+?

Potentially.

The current Reta+ idea centres on adding another biological pathway, such as amylin, to retatrutide.

But an alternative future strategy could be:

redesign retatrutide-like signalling itself.

Rather than adding another drug, researchers could attempt to create a next-generation triple agonist with more favourable intracellular signalling.

That could potentially produce:

• prolonged activity
• better receptor balance
• altered tolerability
• improved metabolic effects

without adding another injection.

What Are the Main Unknowns?

Several major questions remain.

Researchers still need to establish:

• which signalling pathway is optimal for each receptor
• how laboratory bias measurements translate into humans
• whether reduced internalisation improves long-term effectiveness
• whether biased signalling genuinely reduces gastrointestinal effects
• whether different tissues respond differently
• whether signalling bias changes cardiovascular outcomes

The biology remains complex.

Why Is 2026 Important for This Field?

Several important mechanistic studies were published during 2026.

Researchers identified structural features controlling GLP-1 receptor transducer preference, created biased GLP-1/glucagon dual agonists and demonstrated that altered receptor trafficking can prolong cAMP signalling. (PubMed⁠)

That moves biased agonism from a largely theoretical concept toward increasingly rational drug engineering.

The Bigger Picture

Metabolic peptide research has already progressed through several generations.

Generation 1:
Make the peptide last longer.

Generation 2:
Add another receptor.

Generation 3:
Combine several receptors.

The emerging next step may be:

Control exactly how each receptor signals once activated.

That could prove just as important as adding another hormone pathway.

The Bottom Line

Biased agonism means designing a drug so that it activates certain signalling pathways inside a receptor more strongly than others.

For GLP-1-related drugs, researchers are particularly interested in favouring:

G-protein / cAMP signalling

while reducing:

β-arrestin recruitment and receptor internalisation.

Experimental research suggests this may prolong receptor signalling and potentially improve the balance between therapeutic effects and adverse effects. (PubMed⁠)

A 2026 study also demonstrated that biased signalling can be deliberately introduced into GLP-1/glucagon dual agonists, producing strong metabolic effects in preclinical research. (PubMed⁠)

This means the future of metabolic peptide design may not simply be:

GLP-1 → dual agonist → triple agonist → five receptors.

It could also be:

better signalling from the receptors we already know how to target.

That makes biased agonism one of the more important — and less widely understood — areas of next-generation peptide research.

This article is for research and educational purposes only. Signalling bias is an evolving area of pharmacology, and findings from cellular or animal research should not automatically be interpreted as established clinical advantages in humans